Detection of circulating tumor Cells in the context of treatment: Prognostic value in breast cancer patients

Serrano, María José; Sánchez‐Rovira, Pedro; Delgado-Rodriguez, Manuel; Gaforio, José J.

doi:10.4161/cbt.8.8.7834

Cited by 38 publications

(27 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies (4)(5)(6)(7)(8)(9)(10)(11)(12)(13) showed that the presence of CTC was significantly associated with shorter survival in breast cancer. In contrast, other studies (14)(15)(16)(17)(18)(19)(20) failed to show such an association between the presence of CTC and worse prognosis. This discrepancy may result from the rather small sample size of patients enrolled in these studies as well as differences in the time point of blood collection and CTC assays used.…”

Section: Introductioncontrasting

confidence: 44%

See 1 more Smart Citation

Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer

Zhang

Wang

et al. 2012

Clinical Cancer Research

328

196

View full text Add to dashboard Cite

Purpose: The prognostic value of circulating tumor cells (CTC) detected in breast cancer patients is currently under debate. Different time points of blood collections and various CTC assays have been used in the past decades. Here, we conducted the first comprehensive meta-analysis of published literature on the prognostic relevance of CTC, including patients with early and advanced disease.Experimental Design: A comprehensive search for articles published between January 1990 and January 2012 was conducted; reviews of each study were conducted and data were extracted. The main outcomes analyzed were overall survival (OS) and disease-free survival (DFS) in early-stage breast cancer patients, as well as progression-free survival (PFS) and OS in metastatic breast cancer patients. Pooled hazard ratio (HR) and 95% confidence intervals (CIs) were calculated using the random and the fixed-effects models. Subgroup and sensitivity analyses were also conducted.Results: Forty-nine eligible studies enrolling 6,825 patients were identified. The presence of CTC was significantly associated with shorter survival in the total population. The prognostic value of CTC was significant in both early (DFS: HR, 2.86; 95% CI, 2.19-3.75; OS: HR, 2.78; 95% CI, 2.22-3.48) and metastatic breast cancer (PFS: HR, 1.78; 95% CI, 1.52-2.09; OS: HR, 2.33; 95% CI, 2.09-2.60). Further subgroup analyses showed that our results were stable irrespective of the CTC detection method and time point of blood withdrawal.Conclusion: Our present meta-analysis indicates that the detection of CTC is a stable prognosticator in patients with early-stage and metastatic breast cancer. Further studies are required to explore the clinical utility of CTC in breast cancer.

show abstract

Section: Introductioncontrasting

confidence: 44%

“…In 12 studies (6,13,16,17,19,32,34,35,37,39,41,48), more than 1 HR was extracted from each study because multimarkers or multitime points were used to detect CTC in these studies and HRs were reported separately.…”

Section: Global Analysis Of Ctc Effects On Survivalmentioning

confidence: 99%

Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer

Zhang

Wang

et al. 2012

Clinical Cancer Research

328

196

View full text Add to dashboard Cite

show abstract

“…Similar results were observed by Hartkopf et al (2011). Instead of using cutoff point of 5 CTCs, Serrano et al (2009) established a cutoff point of 6 CTCs to validate the clinical outcome. Tewes et al (2009) reported that the concordance between clinical response and CTC levels measured over the course of palliative treatment reached 78%.…”

Section: Breast Cancermentioning

confidence: 99%

Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance

Sun

Yang

Zhou

et al. 2011

J Cancer Res Clin Oncol

164

137

View full text Add to dashboard Cite

show abstract

“…In addition to the 'tumour marker' function of CTCs, these cells remain in the lymphatic/systemic circulation after surgical removal of the primary tumour and are responsible for the later recurrence of the disease. Consequently this undetected cell dissemination by conventional measures is of relevance for cancer progression and has been already demonstrated to be of prognostic impact in several malignancies [7][8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Detection of circulating tumor cells (CTCs) in patients with lung carcinoma by real-time fluorescent quantitative-PCR approach before and after chemotherapy

Ge¹,

Wu²,

Wang³

et al. 2009

Health

View full text Add to dashboard Cite

Circulating tumour cells (CTCs) are referred to the tumour cells that disseminated from the primary tumour and survive in circulating during the proceeding of tumour growth. As surgical treatment evolves and local control has improved, the failure of cancer treatment has largely remained the result of systemic metastasis. Selection of patients most likely to benefit from adjuvant strategies remains problematic. In order to develop a new standard of curative effect, this study was designed to track the number of CTCs in patients with lung cancer during chemotherapy. Methods: Samples of peripheral blood was taken from each lung cancer patients (n=32) on the day before chemotherapy as well as the third week after the chemotherapy cycle. The samples were subjected to real-time fluorescent quantitative reverse-transcriptase polymerase chain reaction (fqRT-PCR). Meanwhile the tumour size was determined by chest X-ray or computed tomograghy. Results Compared to that of pre-chemotherapy, the expression level of cytokeratin (CK) 19 in the patients significantly declined after chemotherapy (t=4.659,P=0.000). The level of CK19 mRNA in patients with small cell lung cancer (SCLC) was higher than that of patients with non-small cell lung cancer (NSCLC) (t=1.944, P=0.061). The decrease of CK19 mRNA level correlated well with the type during the treatment. Relatively the decrease of SCLC is more obvious (t=6.073,P=0.000). The variation of CK19 mRNA level before and after chemotherapy was positively related to the disparity of tumour burden (r=0.593). There was also a significant association between the type (NSCLC vs. SCLC) and the change of tumour size (t=3.686, P=0.001).The positive rate before chemotherapy was 71.9% (23/32), while that after chemotherapy was 37.5% (12/32), indicating that 11 patients converted into negative after chemotherapy. Of the 16 patients which were in Ⅳ-stage, 11 cases were positive (11/16,68.8%). Surprisingly, of the remaining 16 patients which were Ⅱ/Ⅲ stage, 12 cases were regarded as positive according to the criteria (12/6,75%). Conclusions: The real-time flu-orescent quantitative-PCR approach is useful for measuring the relative number of CTCs in a patients' peripheral blood to monitor the effectiveness of treatment, and for designing more comprehensive and reasonable therapeutic regimes at earlier dates for patients. The treatment response can be immediately assessed by serial quantitation of CTCs after chemotherapy, and therefore this method highlights an alternative approach to rapidly access the patient's response to treatment.

show abstract

Detection of circulating tumor Cells in the context of treatment: Prognostic value in breast cancer patients

Cited by 38 publications

References 24 publications

Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer

Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer

Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance

Detection of circulating tumor cells (CTCs) in patients with lung carcinoma by real-time fluorescent quantitative-PCR approach before and after chemotherapy

Contact Info

Product

Resources

About